PALADIN LABS INC.

ANTIZOL

pharmaceutical for use as an antidote to ethylene glycol poisoning;

ANTIZOL-VET

pharmaceutical preparation for use as an antidote to ethylene glycol and methanol poisoning in pets;

BIOENVELOP

Custom manufacturing of film strips and gels for the delivery of pharmaceutical and nutraceutical preparations for others in the medical, dental, health and oral care industries;The following word neutraceutical in classes 5 and 42 should be deleted, and nutraceutical should be inserted.;Film strips and gels for the delivery of pharmaceutical and nutraceutical preparations in the medical, dental, health and oral care industries;BIOLOGICAL ENVELOPE;The wording BIOENVELOP or BIOENVELOPE has no meaning in a foreign language.;Design of film strips and gels for the delivery of pharmaceutical and nutraceutical preparations for others in the medical, dental, health and oral care industries;

CONTRAMID

Color is not claimed as a feature of the mark.;Modified starch used in the manufacture of pharmaceutical products as an agent for controlled or sustained release drug delivery for oral and parenteral administration;

GELICIOUS

natural supplements and immune boosters in gel, tablet, strip or capsule format, namely, vitamins, minerals and food supplements, namely, dietary fibres, omega 3 and flax seed oil;GEL DELICIOUS;

HELIKIT

medical testing kits consisting primarily of diagnostic reagents and specimen containers for clinical or medical laboratory use;

LABOPHARM

MANUFACTURE OF PHARMACEUTICAL PRODUCTS AND PHARMACEUTICAL FORMULATIONS TO THE ORDER AND SPECIFICATION OF OTHERS;The mark consists of the term labopharm with a fanciful design over the letter l consisting of three independent shaded circles and three shaded circles connected by a centrally placed incomplete non-shaded circle.;Color is not claimed as a feature of the mark.;RESEARCH AND DEVELOPMENT FOR OTHERS OF PHARMACEUTICAL PRODUCTS AND PHARMACEUTICAL FORMULATIONS;

T315I MUTATION TREATMENT

The mark consists of grey letters and numbers for T315I with the 3 being a swirl design where the outside is purple and the inside is orange and the words MUTATION TREATMENT are in purple Title case letter with a purple plus sign in front of these words.;T THREE ONE FIVE ONE; T THREE ONE FIFTY ONE;The color(s) grey, purple and orange is/are claimed as a feature of the mark.;Medical testing for diagnostic and prognostic purposes in the field of cancer, kinase inhibitor treatment failure, and genetics; Medical testing for diagnostic and treatment purposes in the field of cancer research, kinase inhibitor treatment failure research, and genetics research; Providing medical information to medical professionals, namely, oncologists and treating physicians for cancer patients, in the form of reports in the field of cancer diagnostics and prognostics; Medical testing services, namely, kinase inhibitor treatment failure and genetic testing for diagnosis and treatment of cancer; Genetic testing for medical purposes;T315I MUTATION TREATMENT;Providing scientific analysis and informational reports based upon results of laboratory testing in the field of kinase inhibitor treatment failure, genetics, epigenetics and cancer; scientific research in the fields of kinase inhibitor treatment failure, genetics, epigenetics and cancer; Laboratory research in the field of the field of cancer research, kinase inhibitor treatment failure, and genetics; Providing laboratory research services in the field of kinase inhibitor treatment failure and genetic testing;